Hepatitis B Virus DNA (Log) Test

If you have been told you have hepatitis B, this is the single most important number for understanding where you stand. It measures how much virus is actively replicating in your liver and predicts your long-term risk of cirrhosis, liver failure, and liver cancer better than almost any other test you can order.

What surprises most people is that the relationship between this number and your risk is not a straight line. Moderate levels can carry the highest risk of liver cancer, while extremely high levels sometimes reflect a different, less inflammatory phase of infection. Reading this number well requires context, and that context can change your entire treatment plan.

What This Test Measures

HBV DNA (hepatitis B virus DNA) is the genetic material of the virus itself, circulating in your blood inside virus particles produced by infected liver cells. Because the amount can range from undetectable to billions of copies per milliliter, labs report it on a log10 scale. Each whole-number jump on this scale means ten times more virus. A result of 5 log10 IU/mL means 100,000 international units per milliliter; a result of 7 log10 IU/mL means 10 million.

Inside your liver cells, the virus maintains a stable template (called cccDNA) that keeps producing new virus particles. The HBV DNA your blood test measures is the downstream output of that template. It is the most direct sign that the virus is actively copying itself, which is what drives liver inflammation, scarring, and cancer risk.

Liver Cancer Risk

This is the most important reason to track this number. In the landmark Taiwanese REVEAL-HBV study following 3,653 people for over 11 years, cumulative liver cancer risk climbed from 1.3% in those with the lowest viral loads to 14.9% in those with the highest. People with HBV DNA at or above 200,000 IU/mL had roughly 6 times the liver cancer risk of those below 60 IU/mL, even after accounting for age, sex, smoking, alcohol, liver enzymes, and cirrhosis.

The relationship is not perfectly straight. In large Korean and multinational cohorts of patients on antiviral therapy, the highest liver cancer risk actually occurred at moderate viral loads (around 5 to 7 log10 IU/mL), with a roughly 5-fold higher risk than the very highest loads. Very high viral loads in HBeAg-positive patients often reflect an early, less inflammatory phase where the immune system is not actively attacking liver cells.

Reconciling the Counterintuitive Finding

This is not a simple "lower is always better" marker. Your HBV DNA level reflects what phase of infection you are in, and different phases carry different risks. Very high viral loads in young, HBeAg-positive people often mean an immune-tolerant phase where the virus replicates freely but causes little damage. Moderate viral loads frequently signal an immune-active phase where your body is fighting the virus, and that fight is what scars the liver and raises cancer risk. The takeaway: any sustained, detectable HBV DNA deserves attention, but the highest cancer risk is not always at the highest number.

Cirrhosis and Liver Scarring

In the same Taiwanese cohort, the risk of progressing to cirrhosis rose steeply with viral load, independent of HBeAg status and liver enzyme levels. People with HBeAg-positive infection and high viral loads showed the most fibrosis on biopsy in Chinese multicenter data. Even among people with normal liver enzymes, lower HBV DNA levels in the 6 to 7 log10 range were associated with more severe fibrosis than levels above 8 log10, again reflecting that immune-active phase where damage accumulates quietly.

Mother-to-Child Transmission

If you are pregnant with hepatitis B, this number determines whether you need antiviral medication during pregnancy to protect your baby. A viral load above 200,000 IU/mL (about 5.3 log10) is the standard cutoff for starting antiviral prophylaxis. Testing before 22 weeks of pregnancy reliably predicts what your level will be at 28 to 30 weeks, when most prophylaxis decisions are made.

Research-Based Reference Ranges

These thresholds come from international guidelines (AASLD) and large East Asian cohorts using standard PCR-based assays. They are decision points used clinically, not personalized targets. Modern assays from different labs typically agree within 0.5 log10, but values should be compared within the same lab over time for the most meaningful trend.

Note that fluctuations of around 0.5 log10 are common between tests and may reflect natural variation rather than true change. In one study, 63% of people with chronic hepatitis B had spontaneous shifts of at least 0.5 log10 over four months.

Tracking Your Trend

A single HBV DNA result rarely tells the full story. The virus naturally fluctuates, assays vary slightly between platforms, and where your level sits within a phase of infection matters more than any single snapshot. What you want to see is direction and durability over months and years.

If you are untreated, retest every 6 to 12 months along with liver enzymes and HBeAg status. If you are starting antiviral therapy, retest at 3 months to confirm a meaningful drop (typically several log units), again at 6 months to confirm continued suppression, and then every 6 months. If you are pregnant, test before 22 weeks to plan prophylaxis. People who stop antiviral therapy need monthly testing for at least the first 6 months to catch any rebound early.

What an Abnormal Result Should Make You Do

A detectable HBV DNA result is the start of a workup, not a verdict. Pair it with HBeAg status, anti-HBe, quantitative HBsAg, ALT and AST, and a fibrosis assessment such as FibroScan, FIB-4, or FibroTest. The pattern matters: high DNA with normal ALT in a young HBeAg-positive person is a different situation than moderate DNA with rising ALT in an HBeAg-negative adult.

You should be working with a hepatologist or gastroenterologist familiar with hepatitis B. If your viral load is above the treatment thresholds in the table above and ALT is elevated, treatment is usually indicated. If you have cirrhosis, treatment is indicated regardless of viral load. Anyone with chronic HBV needs liver cancer surveillance with ultrasound and alpha-fetoprotein every 6 months, particularly if you are over 40, have cirrhosis, have a family history of liver cancer, or are of Asian or African ancestry.

When Results Can Be Misleading

• Spontaneous fluctuation: roughly two-thirds of people with chronic hepatitis B show shifts of 0.5 log10 or more between tests within a few months, without any change in disease activity. One reading near a treatment threshold should always be confirmed.
• Assay-to-assay differences: different labs use different PCR platforms (Roche, Abbott, Cepheid, Siemens). Most agree within 0.5 log10, but switching labs mid-monitoring can create the appearance of change where there is none.
• Immunosuppressive drugs: corticosteroids, rituximab, checkpoint inhibitors, CAR-T therapies, and several biologics can trigger HBV reactivation, causing real and sometimes dangerous spikes in viral load. This is a true biological effect, not a lab artifact, and requires prophylaxis or close monitoring before starting these therapies.
• Low-level viremia near the detection limit: results just above or below the lower limit of quantification can flicker between detectable and undetectable without clinical meaning.